IndraLab
Statements
sparser
"In agreement with the recent report that the deubiquitination activity of DUB3 relies on CDK4/6-mediated phosphorylation of DUB3 and this activity is inhibited by the CDK4/6 inhibitor ( xref ), we demonstrated that treatment of mice with the CDK4/6 inhibitor palbociclib largely sensitized DUB3-proficient prostate tumors to JQ1, but the effect of palbociclib was almost completely abolished by DUB3 knockdown."